Here Are the Facts You Need to Understand ELAN

Shares of Health Care sector company Elanco Animal Health moved 1.8% today, and are now trading at a price of $16.79. The Mid-Cap stock's daily volume was 3,042,322 compared to its average volume of 4,180,391. The S&P 500 index returned a 1.0% performance.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. The company is based in Greenfield and has 9,300 full time employees. Its market capitalization is $8,297,316,352.

10 analysts are following Elanco Animal Health and have set target prices ranging from $16.0 to $23.0 per share. On average, they have given the company a rating of buy. At today's prices, ELAN is trading -14.03% away from its average analyst target price of $19.53 per share.

Over the last year, ELAN's share price has increased by 107.8%, which represents a difference of 81.7% when compared to the S&P 500. The stock's 52 week high is $17.43 per share whereas its 52 week low is $7.88. Elanco Animal Health's average free cash flow over the last 5 years has been $172.13 Million, but they have been decreasing at an average rate of -7.1%. This may prove a challenge to the long term sustainability of the stock's upwards trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 271,000 120,000 151,000 -46.26
2022 452,000 171,000 281,000 -13.27
2021 483,000 159,000 324,000 302.5
2020 -41,000 119,000 -160,000 -290.48
2019 224,000 140,000 84,000 -76.19
2018 487,300 134,500 352,800
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.